Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

IDx-DR Achieves Endpoints in Pivotal FDA Trial of AI-based Diabetic Retinopathy Diagnostic Solution

Posted on: 24 Feb 18

IOWA CITY, Iowa, Feb. 22, 2018 /PRNewswire/ -- IDx, a privately-held AI diagnostics company, today announced that IDx-DR, an AI-based system for the autonomous detection of diabetic retinopathy, met its endpoints in a pivotal FDA trial involving 900 people with diabetes. IDx-DR was developed to assess for diabetic retinopathy during routine office visits with primary care providers, with results available in minutes. Diabetic retinopathy is a leading cause of blindness in the U.S., but vision loss is preventable if the disease is detected and treated early.

IDx-DR has been under review by the FDA since January. The submission, which included data from the clinical trial, was granted expedited review under the FDA's Breakthrough Device program. If cleared by the FDA, IDx-DR is expected to become the first autonomous, AI-based diagnostic system intended for use in the front lines of healthcare.

The trial was conducted at 10 primary care sites across the U.S. to evaluate the diagnostic accuracy of IDx-DR in detecting moderate to severe diabetic retinopathy, including macular edema. The results met the study hypotheses that were developed in consultation with FDA and demonstrated that the IDx-DR system exceeded these performance goals.

"We are very pleased with the diagnostic accuracy and look forward to FDA's expedited review," said Michael Abràmoff, MD, PhD, founder and president of IDx. Abràmoff discussed the study results at today's Macula Society Meeting in Beverly Hills, California. Published results in a peer-reviewed journal are pending.

Findings from the IDx study used real world data collected during the patient care process, rather than data or images procured retrospectively. All tests were performed in a primary care setting by non-clinician staff who received an average of four hours training on the IDx-DR system.

Clinical trial sites have offered favorable feedback. "This technology has great utility and would be solving a real problem," said John Parker, MD, principal investigator at PMG-Research of Wilmington.  "IDx-DR may not only help to identify disease requiring treatment, but the diagnosis also may prompt patients to change their lifestyle and play a more active role in managing their diabetes."

About IDx, LLC
IDx is an AI diagnostics company focused on developing clinically-aligned autonomous algorithms that identify disease in medical images. Its mission is to transform the quality, accessibility, and affordability of global healthcare through the automation of medical diagnosis and treatment.

IDx is a leader in automated medical image analysis. The company recently completed an FDA clinical trial for its first product, IDx-DR, an AI-based diagnostic system that detects diabetic retinopathy. The device is not currently available for sale in the United States but a clearance determination is expected in 2018.

IDx also has products in development for the detection of macular degeneration, glaucoma, Alzheimer's disease, cardiovascular disease, and stroke risk. The company was founded by world renowned retina specialists and has a strategic partnership with IBM Watson Health to distribute its products in the EU.

485 Highway 1 West
Iowa City, IA 52246
Phone:  319-248-5620

IDx Contact:
Laura Shoemaker
Director of Marketing Communications

Media Contact:
Michelle Ronan Noteboom
Amendola Communications

Editor's Details

Mike Wood

Last updated on: 24/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.